Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Germline mutations in the BRCA1 gene are associated with increased cancer risk, yet lack approved chemoprevention targets.
• Mutant BRCA1 impairs base-excision DNA repair, leading to oxidative DNA damage accumulation and heightened cancer susceptibility.

Purpose of the Study:

• To develop a targeted chemoprevention strategy for BRCA1-associated malignancies.
• To identify novel drug candidates that can restore DNA repair activity in the presence of mutant BRCA1.

Main Methods:

• A high-throughput chemical screen was employed to identify compounds that enhance base-excision DNA repair.
• The screen focused on agents that counteract the inhibitory effects of mutant BRCA1 on DNA repair with minimal cytotoxicity.
• Assays were performed to evaluate the impact of identified agents on malignant properties like anchorage-independent growth and tumor progression.

Main Results:

• At least one novel chemopreventive agent was identified.
• This agent demonstrated the ability to enhance base-excision DNA repair in the presence of mutant BRCA1.
• The identified agent reduced malignant properties associated with tumorigenesis, including anchorage-independent growth and tumor progression.

Conclusions:

• This study presents a preclinical proof-of-concept for a novel chemoprevention approach for BRCA1 mutation carriers.
• The identified DNA repair-activating agents represent a new class of chemopreventive drugs.
• This strategy holds promise for reducing the incidence of BRCA1-associated cancers.